0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global ASO-based Drug Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-9F17408
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global ASO based Drug Market Research Report 2024
BUY CHAPTERS

Global ASO-based Drug Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-9F17408
Report
October 2025
Pages:115
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

ASO-based Drug Market Size

The global ASO-based Drug market is projected to grow from US$ 4026 million in 2024 to US$ 12140 million by 2031, at a CAGR of 17.3% (2025-2031), driven by critical product segments and diverse end‑use applications.

ASO-based Drug Market

ASO-based Drug Market

Antisense Oligonucleotides (ASOs) are a class of nucleic acid drugs designed to target specific RNA molecules within cells. They work by binding to complementary RNA sequences, which can modulate gene expression in various ways. ASOs have been developed to treat a wide range of genetic and other diseases
From a downstream perspective, Neuromuscular Diseases accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
ASO-based Drug leading manufacturers including Ionis Pharmaceuticals, Biogen, Sobi, Nippon Shinyaku, Jazz Pharmaceuticals, etc., dominate supply; the top five capture approximately % of global revenue, with Ionis Pharmaceuticals leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global ASO-based Drug market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of ASO-based Drug Market Report

Report Metric Details
Report Name ASO-based Drug Market
Accounted market size in 2024 US$ 4026 million
Forecasted market size in 2031 US$ 12140 million
CAGR 17.3%
Base Year 2024
Forecasted years 2025 - 2031
Segment by Type
  • Intrathecal Injection
  • Intravenous Injections
  • Other
Segment by Application
  • Neuromuscular Diseases
  • hATTR
  • Other
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Ionis Pharmaceuticals, Biogen, Sobi, Nippon Shinyaku, Jazz Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the ASO-based Drug study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

How fast is ASO-based Drug Market growing?

Ans: The ASO-based Drug Market witnessing a CAGR of 17.3% during the forecast period 2025-2031.

What is the ASO-based Drug Market size in 2031?

Ans: The ASO-based Drug Market size in 2031 will be US$ 12140 million.

Who are the main players in the ASO-based Drug Market report?

Ans: The main players in the ASO-based Drug Market are Ionis Pharmaceuticals, Biogen, Sobi, Nippon Shinyaku, Jazz Pharmaceuticals

What are the Application segmentation covered in the ASO-based Drug Market report?

Ans: The Applications covered in the ASO-based Drug Market report are Neuromuscular Diseases, hATTR, Other

What are the Type segmentation covered in the ASO-based Drug Market report?

Ans: The Types covered in the ASO-based Drug Market report are Intrathecal Injection, Intravenous Injections, Other

1 Study Coverage
1.1 Introduction to ASO-based Drug: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global ASO-based Drug Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Intrathecal Injection
1.2.3 Intravenous Injections
1.2.4 Other
1.3 Market Segmentation by Application
1.3.1 Global ASO-based Drug Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Neuromuscular Diseases
1.3.3 hATTR
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global ASO-based Drug Revenue Estimates and Forecasts 2020-2031
2.2 Global ASO-based Drug Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global ASO-based Drug Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global ASO-based Drug Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Intrathecal Injection Market Size by Players
3.3.2 Intravenous Injections Market Size by Players
3.3.3 Other Market Size by Players
3.4 Global ASO-based Drug Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global ASO-based Drug Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global ASO-based Drug Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America ASO-based Drug Market Size by Type (2020-2031)
6.4 North America ASO-based Drug Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America ASO-based Drug Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe ASO-based Drug Market Size by Type (2020-2031)
7.4 Europe ASO-based Drug Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe ASO-based Drug Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific ASO-based Drug Market Size by Type (2020-2031)
8.4 Asia-Pacific ASO-based Drug Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific ASO-based Drug Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America ASO-based Drug Market Size by Type (2020-2031)
9.4 Central and South America ASO-based Drug Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America ASO-based Drug Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa ASO-based Drug Market Size by Type (2020-2031)
10.4 Middle East and Africa ASO-based Drug Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa ASO-based Drug Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Corporation Information
11.1.2 Ionis Pharmaceuticals Business Overview
11.1.3 Ionis Pharmaceuticals ASO-based Drug Product Features and Attributes
11.1.4 Ionis Pharmaceuticals ASO-based Drug Revenue and Gross Margin (2020-2025)
11.1.5 Ionis Pharmaceuticals ASO-based Drug Revenue by Product in 2024
11.1.6 Ionis Pharmaceuticals ASO-based Drug Revenue by Application in 2024
11.1.7 Ionis Pharmaceuticals ASO-based Drug Revenue by Geographic Area in 2024
11.1.8 Ionis Pharmaceuticals ASO-based Drug SWOT Analysis
11.1.9 Ionis Pharmaceuticals Recent Developments
11.2 Biogen
11.2.1 Biogen Corporation Information
11.2.2 Biogen Business Overview
11.2.3 Biogen ASO-based Drug Product Features and Attributes
11.2.4 Biogen ASO-based Drug Revenue and Gross Margin (2020-2025)
11.2.5 Biogen ASO-based Drug Revenue by Product in 2024
11.2.6 Biogen ASO-based Drug Revenue by Application in 2024
11.2.7 Biogen ASO-based Drug Revenue by Geographic Area in 2024
11.2.8 Biogen ASO-based Drug SWOT Analysis
11.2.9 Biogen Recent Developments
11.3 Sobi
11.3.1 Sobi Corporation Information
11.3.2 Sobi Business Overview
11.3.3 Sobi ASO-based Drug Product Features and Attributes
11.3.4 Sobi ASO-based Drug Revenue and Gross Margin (2020-2025)
11.3.5 Sobi ASO-based Drug Revenue by Product in 2024
11.3.6 Sobi ASO-based Drug Revenue by Application in 2024
11.3.7 Sobi ASO-based Drug Revenue by Geographic Area in 2024
11.3.8 Sobi ASO-based Drug SWOT Analysis
11.3.9 Sobi Recent Developments
11.4 Nippon Shinyaku
11.4.1 Nippon Shinyaku Corporation Information
11.4.2 Nippon Shinyaku Business Overview
11.4.3 Nippon Shinyaku ASO-based Drug Product Features and Attributes
11.4.4 Nippon Shinyaku ASO-based Drug Revenue and Gross Margin (2020-2025)
11.4.5 Nippon Shinyaku ASO-based Drug Revenue by Product in 2024
11.4.6 Nippon Shinyaku ASO-based Drug Revenue by Application in 2024
11.4.7 Nippon Shinyaku ASO-based Drug Revenue by Geographic Area in 2024
11.4.8 Nippon Shinyaku ASO-based Drug SWOT Analysis
11.4.9 Nippon Shinyaku Recent Developments
11.5 Jazz Pharmaceuticals
11.5.1 Jazz Pharmaceuticals Corporation Information
11.5.2 Jazz Pharmaceuticals Business Overview
11.5.3 Jazz Pharmaceuticals ASO-based Drug Product Features and Attributes
11.5.4 Jazz Pharmaceuticals ASO-based Drug Revenue and Gross Margin (2020-2025)
11.5.5 Jazz Pharmaceuticals ASO-based Drug Revenue by Product in 2024
11.5.6 Jazz Pharmaceuticals ASO-based Drug Revenue by Application in 2024
11.5.7 Jazz Pharmaceuticals ASO-based Drug Revenue by Geographic Area in 2024
11.5.8 Jazz Pharmaceuticals ASO-based Drug SWOT Analysis
11.5.9 Jazz Pharmaceuticals Recent Developments
12 ASO-based DrugIndustry Chain Analysis
12.1 ASO-based Drug Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 ASO-based Drug Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global ASO-based Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
 Table 1. Global ASO-based Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global ASO-based Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global ASO-based Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global ASO-based Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global ASO-based Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global ASO-based Drug Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global ASO-based Drug Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global ASO-based Drug by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ASO-based Drug as of 2024)
 Table 11. Global ASO-based Drug Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global ASO-based Drug Companies Headquarters
 Table 13. Global ASO-based Drug Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global ASO-based Drug Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global ASO-based Drug Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global ASO-based Drug Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global ASO-based Drug Revenue by Application (2026-2031) & (US$ Million)
 Table 21. ASO-based Drug High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America ASO-based Drug Growth Accelerators and Market Barriers
 Table 25. North America ASO-based Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe ASO-based Drug Growth Accelerators and Market Barriers
 Table 27. Europe ASO-based Drug Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific ASO-based Drug Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific ASO-based Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America ASO-based Drug Investment Opportunities and Key Challenges
 Table 31. Central and South America ASO-based Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa ASO-based Drug Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa ASO-based Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Ionis Pharmaceuticals Corporation Information
 Table 35. Ionis Pharmaceuticals Description and Major Businesses
 Table 36. Ionis Pharmaceuticals Product Features and Attributes
 Table 37. Ionis Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Ionis Pharmaceuticals Revenue Proportion by Product in 2024
 Table 39. Ionis Pharmaceuticals Revenue Proportion by Application in 2024
 Table 40. Ionis Pharmaceuticals Revenue Proportion by Geographic Area in 2024
 Table 41. Ionis Pharmaceuticals ASO-based Drug SWOT Analysis
 Table 42. Ionis Pharmaceuticals Recent Developments
 Table 43. Biogen Corporation Information
 Table 44. Biogen Description and Major Businesses
 Table 45. Biogen Product Features and Attributes
 Table 46. Biogen Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Biogen Revenue Proportion by Product in 2024
 Table 48. Biogen Revenue Proportion by Application in 2024
 Table 49. Biogen Revenue Proportion by Geographic Area in 2024
 Table 50. Biogen ASO-based Drug SWOT Analysis
 Table 51. Biogen Recent Developments
 Table 52. Sobi Corporation Information
 Table 53. Sobi Description and Major Businesses
 Table 54. Sobi Product Features and Attributes
 Table 55. Sobi Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Sobi Revenue Proportion by Product in 2024
 Table 57. Sobi Revenue Proportion by Application in 2024
 Table 58. Sobi Revenue Proportion by Geographic Area in 2024
 Table 59. Sobi ASO-based Drug SWOT Analysis
 Table 60. Sobi Recent Developments
 Table 61. Nippon Shinyaku Corporation Information
 Table 62. Nippon Shinyaku Description and Major Businesses
 Table 63. Nippon Shinyaku Product Features and Attributes
 Table 64. Nippon Shinyaku Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Nippon Shinyaku Revenue Proportion by Product in 2024
 Table 66. Nippon Shinyaku Revenue Proportion by Application in 2024
 Table 67. Nippon Shinyaku Revenue Proportion by Geographic Area in 2024
 Table 68. Nippon Shinyaku ASO-based Drug SWOT Analysis
 Table 69. Nippon Shinyaku Recent Developments
 Table 70. Jazz Pharmaceuticals Corporation Information
 Table 71. Jazz Pharmaceuticals Description and Major Businesses
 Table 72. Jazz Pharmaceuticals Product Features and Attributes
 Table 73. Jazz Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Jazz Pharmaceuticals Revenue Proportion by Product in 2024
 Table 75. Jazz Pharmaceuticals Revenue Proportion by Application in 2024
 Table 76. Jazz Pharmaceuticals Revenue Proportion by Geographic Area in 2024
 Table 77. Jazz Pharmaceuticals ASO-based Drug SWOT Analysis
 Table 78. Jazz Pharmaceuticals Recent Developments
 Table 79. Raw Materials Key Suppliers
 Table 80. Distributors List
 Table 81. Market Trends and Market Evolution
 Table 82. Market Drivers and Opportunities
 Table 83. Market Challenges, Risks, and Restraints
 Table 84. Research Programs/Design for This Report
 Table 85. Key Data Information from Secondary Sources
 Table 86. Key Data Information from Primary Sources


List of Figures
 Figure 1. ASO-based Drug Product Picture
 Figure 2. Global ASO-based Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Intrathecal Injection Product Picture
 Figure 4. Intravenous Injections Product Picture
 Figure 5. Other Product Picture
 Figure 6. Global ASO-based Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 7. Neuromuscular Diseases
 Figure 8. hATTR
 Figure 9. Other
 Figure 10. ASO-based Drug Report Years Considered
 Figure 11. Global ASO-based Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 13. Global ASO-based Drug Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global ASO-based Drug Revenue Market Share by Region (2020-2031)
 Figure 15. Global ASO-based Drug Revenue Market Share Ranking (2024)
 Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 17. Intrathecal Injection Revenue Market Share by Player in 2024
 Figure 18. Intravenous Injections Revenue Market Share by Player in 2024
 Figure 19. Other Revenue Market Share by Player in 2024
 Figure 20. Global ASO-based Drug Revenue Market Share by Type (2020-2031)
 Figure 21. Global ASO-based Drug Revenue Market Share by Application (2020-2031)
 Figure 22. North America ASO-based Drug Revenue YoY (2020-2031) & (US$ Million)
 Figure 23. North America Top 5 Players ASO-based Drug Revenue (US$ Million) in 2024
 Figure 24. North America ASO-based Drug Revenue (US$ Million) by Type (2020 - 2031)
 Figure 25. North America ASO-based Drug Revenue (US$ Million) by Application (2020-2031)
 Figure 26. US ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 27. Canada ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 28. Mexico ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 29. Europe ASO-based Drug Revenue YoY (2020-2031) & (US$ Million)
 Figure 30. Europe Top 5 Players ASO-based Drug Revenue (US$ Million) in 2024
 Figure 31. Europe ASO-based Drug Revenue (US$ Million) by Type (2020-2031)
 Figure 32. Europe ASO-based Drug Revenue (US$ Million) by Application (2020-2031)
 Figure 33. Germany ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 34. France ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 35. U.K. ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 36. Italy ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 37. Russia ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 38. Asia-Pacific ASO-based Drug Revenue YoY (2020-2031) & (US$ Million)
 Figure 39. Asia-Pacific Top 8 Players ASO-based Drug Revenue (US$ Million) in 2024
 Figure 40. Asia-Pacific ASO-based Drug Revenue (US$ Million) by Type (2020-2031)
 Figure 41. Asia-Pacific ASO-based Drug Revenue (US$ Million) by Application (2020-2031)
 Figure 42. Indonesia ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 43. Japan ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 44. South Korea ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 45. Australia ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 46. India ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 47. Indonesia ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 48. Vietnam ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 49. Malaysia ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 50. Philippines ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 51. Singapore ASO-based Drug Revenue (2020-2031) & (US$ Million)
 Figure 52. Central and South America ASO-based Drug Revenue YoY (2020-2031) & (US$ Million)
 Figure 53. Central and South America Top 5 Players ASO-based Drug Revenue (US$ Million) in 2024
 Figure 54. Central and South America ASO-based Drug Revenue (US$ Million) by Type (2020-2031)
 Figure 55. Central and South America ASO-based Drug Revenue (US$ Million) by Application (2020-2031)
 Figure 56. Brazil ASO-based Drug Revenue (2020-2025) & (US$ Million)
 Figure 57. Argentina ASO-based Drug Revenue (2020-2025) & (US$ Million)
 Figure 58. Middle East and Africa ASO-based Drug Revenue YoY (2020-2031) & (US$ Million)
 Figure 59. Middle East and Africa Top 5 Players ASO-based Drug Revenue (US$ Million) in 2024
 Figure 60. South America ASO-based Drug Revenue (US$ Million) by Type (2020-2031)
 Figure 61. Middle East and Africa ASO-based Drug Revenue (US$ Million) by Application (2020-2031)
 Figure 62. GCC Countries ASO-based Drug Revenue (2020-2025) & (US$ Million)
 Figure 63. Israel ASO-based Drug Revenue (2020-2025) & (US$ Million)
 Figure 64. Egypt ASO-based Drug Revenue (2020-2025) & (US$ Million)
 Figure 65. South Africa ASO-based Drug Revenue (2020-2025) & (US$ Million)
 Figure 66. ASO-based Drug Industry Chain Mapping
 Figure 67. Channels of Distribution (Direct Vs Distribution)
 Figure 68. Bottom-up and Top-down Approaches for This Report
 Figure 69. Data Triangulation
 Figure 70. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Seventh Sense AI

RELATED REPORTS

Global Pharmacy Chatbot Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10T20319
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Inline Pharmaceutical Packaging Leak Detection System Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-6Q20319
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Radiological Marker Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35Z19949
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Pharmaceutical Biomanufacturing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-26E19785
Wed Dec 03 00:00:00 UTC 2025

Add to Cart